Prognostic Relevance of Surface Markers in Adult de novo Acute Myeloblasts Leukemias: A Prospective Study of the Groupe d'Etude Immunologique des Leucemies (G.E.I.L.)

References

• Vaughan W. P., Civin C. I., Weisenburger D. D., Karp J. E., Graham M. L., Sanger W. G., Grierson H. L., Joshi S. S., Burke P. J. Acute leukemia expressing the normal human hemopoietic stem cell membrane glycoprotein CD34 (My 10). Leukemia 1988; 2: 661–666
   PubMed Web of Science ®Google Scholar
• Borowtiz M. J., Gockerman J. P., Moore J. O., Civin C. I., Page S. O., Robertson J., Bigner S. H. Clinicopathologic and cytogenetic features of CD 34 (My 10)-positive acute nonlymphocytic leukemia. Am. J. Clin. Pathol. 1989; 91: 2–270
   Google Scholar
• Campos L., Guyotat D., Archimbaud E., Devaux Y., Treille D., Larese A., Maupas J., Gentilhomme O., Ehrsam A., Fiere D. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br. J. Haematol. 1989; 72: 161–166
   PubMed Web of Science ®Google Scholar
• Geller R. B., Zahurak M., Hurwitz C. A., Burcke P. J., Karp J. E., Piantadosi S., Civin C. I. Prognostic importance of immunotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (My10). Br. J. Haematol. 1990; 76: 340–347
   PubMed Web of Science ®Google Scholar
• Guinot M., Sanz G. F., Sempere A., Arilla M. G., Jarque I., Gomis F., Sanz M. A. Prognostic value of CD34 in de novo acute myeloblasts leukemia. Br. J. Haematol. 1991; 78: 533–534
   Web of Science ®Google Scholar
• Lee E. J., Yang J., Leavitt R. D., Testa J. R., Civin C. I., Forrest A., Schiffer C. A. The significance of CD34 and TdT determination in patients with untreated de novo Acute myeloid leukemia. Leukemia 1992; 6: 1203–1209
   PubMed Web of Science ®Google Scholar
• Solary E., Casasnovas R. O., Campos L., Béné M C, Faure G., Maingon P., Falkenrodl A., Lenormand B., Genetet N., The Groupe d'Etude Immunologique des Leucémies (GEIL). Surface markers in adult myeloblasts leukemia: correlation of CD19+, CD34+, and CD14+/DR-phenotypes with shorter survival. Leukemia 1992; 6: 393–399
   PubMed Web of Science ®Google Scholar
• Holowiecki J., Lutz D., Krzemien S., Stella-Holowiecka B., Graf F., Kelenyi G., Schranz V., Callae V., Brugiatelli M., Neri A., Magyarlaki T., Ihle R., Jagoda K., Rudzka E. CD 15 antigen detected by the VIM-D5 monoclonal antibody for prediction of ability to achieve complete remission in acute nonlymphocytic leukemia. Acta Haematol. 1986; 76: 16–19
   PubMed Web of Science ®Google Scholar
• Schwarzinger I., Valent P., Koller U., Marosi C., Schneider B., Haas O., Knapp W., Lechner K., Bettelheim P. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J. Clin. Oncol. 1990; 8: 423–430
   PubMed Web of Science ®Google Scholar
• Griffin J. D., Davis R., Nelson D. A., Davey F. R., Mayer R. J., Schiffer C., McIntyre O. R., Bloomfield C. D. Use of surface marker analysis to predict outcome of adult myeloblastic leukemia. Blood 1986; 68: 1232–1241
   PubMed Web of Science ®Google Scholar
• Bradstock K. F., Hoffbrand A. V., Ganeshaguru K., Llewellin P., Patterson K., Wonke B., Prentice A. G., Bennett M., Pizzolo G., Bollum F. J., Janossy G. Terminal de-oxynucleotidyl transferase expression in acute non-lymphoid leukemia: an analysis by immunofluorescence. Br. J. Haematol. 1981; 47: 133–143
   Web of Science ®Google Scholar
• Jani P., Verbi W., Greaves M. F., Bevan D., Bollum F. Terminal deoxynuleotidyl transferase in acute myeloid leukemia. Leuk., Res. 1983; 7: 17–29
   PubMed Web of Science ®Google Scholar
• Benedetto P., Mertelsmann R., Szatrowski T. H., Andreef M., Gee T., Arlin Z., Kempin S., Clarkson B. Prognostic-significance of terminal deoxynucleotidyl transferase activity in acute non-lymphoblastic leukemia. J. Clin. Oncol. 1986; 4: 489–495
   PubMed Web of Science ®Google Scholar
• Lo Coco F., Lopez M., Pasqualetti D., Montefusco E., Cafolla A., Monarca B., Sgadari C., De Rossi G. Terminal transferase positive acute myeloid leukemia: immunophenotypic characterisation and response to induction therapy. Hematol. Oncol. 1989; 7: 162–174
   Google Scholar
• Jensen A. W., Hokland M., Jorgensen H., Justesen J., Ellegaard J., Hokland P. Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: identification of a group of patients with similar T-cell receptor b and d rearrangements and course of disease suggestive of poor prognosis. Blood 1991; 78: 1292–1300
   PubMed Web of Science ®Google Scholar
• Kita K., Miwa H., Nakase K., Kawakami K., Kobayashi T., Shirakawa S., Tanaka I., Ohta C., Tsutani H., Oguma S., Kyo T., Dohy H., Kamada N., Nasu K., Uchino H. Clinical importance of CD7 expression in acute myelocytic leukemia. Blood 1993; 81: 2399–2405
   PubMed Web of Science ®Google Scholar
• Kasparu H., Koller U., Krieger O., Nowotny H., Tuchler H., Lutz D. Significance of CD7 and TdT positivity in AML patients. Tissue Antigens 1989; 33: 240
   Google Scholar
• Lo Coco F., De Rossi G., Pasqualetti D., Lopez M., Diverio D., Latagliata R., Fenu S., Mandelli F. CD7 positive acute myeloid leukemia: a subtype associated with cell immaturity. Br. J. Haematol. 1989; 73: 480–485
   PubMed Web of Science ®Google Scholar
• Swirsky D. M., Greaves M. F., Gray R. G., Rees J. K. H. Terminal deoxynucleotidyl transferase and HLA-DR expression appear unrelated to prognosis of acute myeloid leukemia. Br. J. Haematol. 1988; 70: 193–198
   PubMed Web of Science ®Google Scholar
• Merle-Beral H., Nguyen Cong Due L., Leblond V., Boucheix C., Michel A., Chastang C., Debre P. Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukemia. Br. J. Haematol. 1989; 73: 323–330
   PubMed Web of Science ®Google Scholar
• Cross A. H., Goorha R. M., Nuss R., Behm F. G., Murphy S. B., Kalwinsky D. K., Raimondi S., Kitchingman G. R., Mirro J. Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. Blood 1988; 72: 579–587
   PubMed Web of Science ®Google Scholar
• Gucalp R., Paietta E., Weinberg V., Papenhausen P., Dutcher J. P., Wiernick P. H. Terminal transferase expression in acute myeloid leukemia: biology and prognosis. Br. J. Haematol. 1991; 77: 48–54
   Web of Science ®Google Scholar
• Willman C. L., Kopecky K. J., Appelbaum F., Grever M. R., Head D. R., Elias L., Balcerzak S. P., Mills G. M., Hynes H. E. Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression is associated with a decreased complete remission (CR) rate and CD34-positive patients more frequently achieve CR with high-dose cytosine arabinoside. Proceedings of the American Society of Clinical Oncology 1992; 11: 2262
   Google Scholar
• Drexler G. H., Thiel E., Ludwig W. D. Acute myeloid leukemias expressing lymphoid-associated antigens: Diagnostic incidence and prognostic significance. Leukemia 1993; 7: 489–498
   PubMed Web of Science ®Google Scholar
• Ball E. D., Davis E. B., Griffin J. D., Mayer R. J., Davey F. R., Arthuer D. C., Wunster-Hill D., Noll W., Tarek-Elghetany M., Allen S. L., Rai K., Lee E. J., Schiffer L. A., Bloomfield C. D. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991; 77: 2242–2250
   PubMed Web of Science ®Google Scholar